Status:
COMPLETED
Phase I Combination Ixabepilone + Cisplatin
Lead Sponsor:
R-Pharm
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non...
Eligibility Criteria
Inclusion
- Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation
- Inclusion Criteria:
- Men and women age ≥ 18
- Exclusion:
- More than 2 prior chemotherapy containing regimens for metastatic disease
- No prior exposure to cisplatin or ixabepilone
- Expansion Phase Subjects: Advanced Non-small cell lung cancer
- Inclusion Criteria:
- Men and women age ≥ 18
- Exclusion:
- No prior chemotherapy-containing regimen for metastatic disease
- No prior exposure to cisplatin or ixabepilone
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00832117
Start Date
May 1 2009
End Date
January 1 2011
Last Update
October 28 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
2
The Cancer Institute Of New Jersey
New Brunswick, New Jersey, United States, 08901
3
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
4
Local Institution
Lucca, Italy, 55100